Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

3,518 total articles

Truist Lifts Gilead Sciences Price Target to $145, Cites Yeztugo Momentum and Pipeline Updates

Truist Lifts Gilead Sciences Price Target to $145, Cites Yeztugo Momentum and Pipeline Updates

Truist Securities raised its price target for Gilead Sciences to $145 from $140 while retaining a Buy rating, citing updated launch guidance and stronger prescription trends for the company’s HIV drug Yeztugo. The move follows Gilead’s fiscal 2025 pre-report and adjustments to near-term commercialization expectations across several products, and co…

Truist Lifts Nuvation Bio Target to $13, Cites Strong Ibtrozi Uptake

Truist Lifts Nuvation Bio Target to $13, Cites Strong Ibtrozi Uptake

Truist Securities increased its price target on Nuvation Bio Inc to $13.00 from $11.00 and kept a Buy rating following the company’s fourth-quarter 2025 pre-report and a one-on-one meeting with management. The firm highlighted stronger-than-expected early uptake of Ibtrozi and the drug’s positioning in the ROS1 treatment landscape, while noting pot…